Safety of an extended-release injectable moxidectin suspension formulation (ProHeart(®) 12) in dogs

BACKGROUND: The safety of ProHeart® 12 (PH 12; extended-release injectable suspension; 10% moxidectin in glyceryl tristearate microspheres) was evaluated in four studies using Beagle dogs and one study using ivermectin-sensitive Collies. The recommended dose is 0.5 mg/kg subcutaneously once yearly....

Descripción completa

Detalles Bibliográficos
Autores principales: Krautmann, Matthew J., Mahabir, Sean, Fielder, Ann, Collard, Wendy, Wolthuis, Tracie L., Esch, Kevin, Morton, Tracy, Alleman, Kent, Luo, Laibin, McCandless, Erin, Nederveld, Steven, Kryda, Kristina, Carroll, Ryan, Boucher, Joseph F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728954/
https://www.ncbi.nlm.nih.gov/pubmed/31492168
http://dx.doi.org/10.1186/s13071-019-3690-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728954/
https://www.ncbi.nlm.nih.gov/pubmed/31492168
http://dx.doi.org/10.1186/s13071-019-3690-6

Ejemplares similares